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Abstract 
Diabetes mellitus (DM) is a major world health concern especially DM types 2. In Malaysia, about 2.6 
million adults were diagnosed with diabetes and most of them turn to herbal medicine for treatment. 
Vernonia amygdalina or locally known as bitter leaf is believed by the local people and traditional 
inhaler to reduce blood glucose level. This study aims to prove the antidiabetic property of Malaysian 
local V. amygdalina as claim by the local Malaysian. V. amygdalina aqueous extract was prepared by 
reflux method and was further concentrated. Twenty male Sprague Dawley rats were divided into 4 
groups; non-diabetic rats as normal control (NC), diabetic induced rats as diabetic control (DC), diabetic 
induced rats treated with 150 mg/kg metformin and diabetic induced rats treated with 50 mg/kg V. 
amygdalina aqueous extract. The diabetic rats were induced by using 40 mg/kg of Streptozotocin (STZ). 
The study was conducted for 28 days. Body weights (BW) were taken at weekly interval for 4 weeks. 
Fasting blood glucose was measured in 3 day intervals. At the end of experiment, blood samples were 
collected for lipid profile test and insulin secretion assay. There were no significant differences in BW, 
relative organ weight (ROW) and no organs abnormalities were observed in all experimental groups. 
Significant decreases in triglycerides, total cholesterol and fasting blood glucose gave a prove evidence 
that V. amygdalina possessing antidiabetic property. However, the levels of insulin in diabetic induced 
rats treated with V. amygdalina aqueous extract were not significant as compared to the diabetic induced 
rats treated with metformin. The aqueous extract of V. amygdalina has antidiabetic activity. This work 
supports the folk use of this plant in treating diabetes. This antidiabetic property of Malaysian V. 
amygdalina may due to its phytochemical constituents as our previous study revealed the high contents 
of flavonoids and terpenoids. However, the aqueous extract of V. amygdalina did not act through 
regulation of insulin hormone since there was no significant change in insulin level. 
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Introduction 
Diabetes mellitus (DM) is a chronic disease occurs due to lack of insulin production by the 
pancreas, known as Type 1 DM (T1DM) or the ineffectiveness of the body for insulin usage 
known as type 2 DM (T2DM). In definition, DM is a group of metabolic disease with 
characteristic of elevated blood glucose level, a condition known as hyperglycemia (Wild et 
al., 2004) [46]. DM can develop through years without showing symptoms or symptoms may be 
diagnosed as other conditions. Complication arises from DM includes cardiovascular disease, 
neuropathy, retinopathy and kidney disease, are irreversible once they develop and may result 
in disability for the person having the disease (International Diabetes Federation, 2012) [20]. 
T1DM usually occurs in children and the frequency is low relative to the T2DM, accounting 
for 10% or less of the total number of people with diabetes (Wild et al., 2004 International 
Diabetes Federation, 2012; Zimmet et al., 2001) [46, 20]. As for T2DM, it predominantly affects 
middle-ages and older peoples, however, concern rises as the number of T2DM patients have 
increased among children and adolescents (Rosenbloom at al., 1999; Fagot-Campagna et al., 
2001; Arslanian, 2004) [38, 12, 3]. 
The number of total death from DM are estimated to be elevated by more than 50% by the year 
2030 with the disease predicted to be the seventh leading cause of death [1]. DM happens 
throughout the world, and it is most common in the developed countries, especially for T2DM. 
Malaysia has become top 10 countries with highest prevalence in diabetes with 11.6% in 2010 
and expected to increase up to 13.8% in 2030 (Shaw et al., 2009) [41]. According to National 
Health Morbidity Survey (NHMS) of Malaysia, in 2011, the prevalence of diabetes has 
elevated by 31.0% in the period of 5 years, from 11.6% in 2006 to 15.2% in 2011 (NHMS, 
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2014) [31]. another study shows that there are about 2.6 million 
Malaysian adults with the age of 18 years and above are 
diagnosed with diabetes (Feisul and Azmi, 2013) [13]. 
Modern pharmaceuticals frequently employed chemicals and 
synthetic drugs, which believed to have adverse impact on 
health. Therefore, people are turning towards the use of 
natural as remedies of diseases or wounds. Thus, medicinal 
plant has become an alternative for treatment and prevention 
of certain diseases because it was believed to have lesser side 
effects. The medicinal value of plants can be found in the 
leaves, roots or other part of plants, arising from the rich 
component of phytochemicals and secondary metabolites. 
Plants remain to be the mainstay of the health care system in 
the rural area due to the limited access to modern health 
facilities. Despite that, the usage of the plant is depends on the 
ethnic beliefs, traditional usage and the availability of the 
plant itself. 
Phytochemical defined as bioactive non-nutrient plant 
compounds that can be found in fruits, vegetables, grains and 
other plant foods that have been associated in reducing the 
risk of major chronic disease (Liu, 2004) [24]. The medicinal 
value of herbal plants lies in the phytochemical compounds 
that produce a definite physiological action on the human 
body (Mithraja et al., 2011) [30]. However, samples of 
medicinal plant from different plant varieties and 
geographical origin have different complex chemical mixture 
(Sim et al., 2004) [43]. 
Currently, V. amygdalina is popular among diabetes patients 
in Malaysia. They were claimed that the leaves of V. 
amygdalina have a hypoglycemic activity which able to 
lowering blood glucose level. The leaves were boiled with 
water to make a decoction and will consume two times per 
day. The leaves of V. amygdalina were also consumed as 
vegetables and used as condiments in a meal (Arhoghro et al., 
2009) [2]. V. amygdalina is a regenerating soft wooded shrub 
of 2 to 10 meters in height with petiolate leaves of around 6 
mm in diameter (Georgewill et al., 2009; Yeap et al., 2004) 
[15, 47]. In Malaysia, V. amygdalina also known as bitter leaf 
due to its bitter taste (Akah et al., 2009; Ong et al., 2011) [1, 
33]. Traditional practices in other countries have been found to 
use V. amygdalina as a treatment in diabetes mellitus. In 
Nigeria, V. amygdalina was cited as the most popular 
antidiabetic herbal medicine. V. amygdalina leaves were 
squeezed until the juice comes out and mixed with water. The 
juice was also mixed with potash salt and honey to treat 
diabetes mellitus (Gbolade, 2009) [14]. Several studies have 
been reported that V. amygdalina exhibited the characteristics 
of antidiabetic (Akah et al., 2009; Ong et al., 2011; Ekpo et 
al., 2007; Atangwho et al., 2010) [1, 33, 10, 4]. 
However, the geographical origin, locality and climate 
conditions could influence the biological activities of the 
plants (Cosentino et al., 1999; Hossain and Nagooru, 2011; 
Hossain et al., 2013) [8, 19, 18] as they have different complex 
chemical mixure (Sim et al., 2004) [43]. Certain metabolites or 
contents are only synthesized and increased under specific 
environments. For example, in Rosmarinus officinalis, the 
content of terpene was affected by carbon dioxide, water 
supply and seasonally (Yusmazura et al., 2016) [48]. 
Furthermore, previous studies have demonstrated that in 
different environments of medicinal plants growth, the 
contents of secondary metabolites produce were different. 
Therefore, the medicinal qualities produce were varied 
(Penuelas and Llusia, 1997). A study on Sinopodophyllum 
hexandrum, an herbaceous perennial plant showed that in the 
different locations throughout China, the active ingredients of 
the roots and rhizomes significantly affected, indicating that 
ecological and geographical differences influence the content 
of plants [26]. A preliminary study of the essential oil from 
Xylopia aethiopica has also demonstrated that the 
composition of essential oil was quantitatively difference 
according to the climate conditions, soil, geographical origin 
and genetic factors (Liu et al., 2015; Elhassan and Ayoub, 
2014) [25, 11]. 
Therefore, the phytochemical contents of Malaysian V. 
amygdalina have been identified in our previous study 
(Yusmazura et al., 2016) [48]. Thus, this present study aims to 
investigate the antidiabetic property of Malaysia V. 
amygdalina as claimed by local people and to prove that the 
respective biological effect is due to its phytochemical 
contents. The STZ-diabetic rats were used as an animal 
model. The use of STZ induced hyperglycemia rat has been 
described as a useful experimental animal model in diabetic 
studies (Rerup, 1970). This procedure has been used in over 
7600 PubMed citations making this the most used animal 
model to diabetic study of human (Tom et al., 1992). Many 
studies were revealed that the rats administered with STZ in 
dose range of 40 - 65 mg/kg, have been developed moderate 
and stable non-fasting hyperglycemia without any significant 
changes in plasma insulin levels. STZ causes only minor 
damage to pancreatic beta cell mass, producing T2DM. 
Hence, this model is found to be an advantageous tool for 
investigation of antidiabetic agents in the treatment of T2DM. 
 
Materials and Methods 
Plant material 
The fresh leaves of V. amygdalina were collected from 
Bachok, Kota Bharu, Kelantan, Malaysia. The identification 
of the plant was performed by Natural Medicinal Products 
Centre, Kulliyah of Pharmacy, and International Islamic 
University Malaysia (IIUM) with voucher specimen number 
PIIUM 0233. The name of plant also been checked with 
www.theplantlist.org.  
 
Preparation of V. amygdalina aqueous extract 
The leaves were cleaned with towel to remove any debris and 
dust. After that, they were dried in an oven at 55°C ± 1°C for 
72 hours prior to crush into coarse powder. The 25 g of V. 
amygdalina coarse powder was extracted in 250 ml of 
distilled water at 60°C ± 1°C for 72 hours. The extract was 
filtered and further dried in an oven incubator at 37°C. The 
solid residue was referred as aqueous extract and the 
percentage of yield was calculated.  
 
Animal study 
Twenty male Sprague Dawley (SD) rats were obtained from 
Animal Research and Service Center (ARASC), Universiti 
Sains Malaysia (USM), Kubang Kerian, Kelantan. The rats 
weighing from 250-300 g and 8-12 weeks old were chosen as 
an experimental model. The rats were kept in individual 
cages. Water and standard pellet food are available at all 
times (ad libitum). The rats were allowed to acclimatize for 
one week prior to the experiment. The Principles of 
Laboratory Animal Care (NIH, 1985) were followed during 
the experimentation period. The experimental protocol was 
approved by the Animal Ethics Committee, USM (AECUSM) 
under USM/Animal Ethics Approval/2012/(82)(418). The 
ARRIVE Guidelines for reporting animal research was apply 
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Induction of diabetes with streptozotocin (STZ) 
The rats (n=15) were fasted for overnight prior to single intra 
peritoneal injection of 40 mg/kg of body weight (BW) of STZ 
((Nacalai Tesque, Japan). STZ was freshly dissolved in 1 ml 
of citrate buffer (pH4.5) prior to injection. After 7 days of 
injection, fasting blood glucose (FBG) level was measured 
with glucometer (Accu-Chek Performa). Rats with FBG of 12 
mmol/L and higher were considered diabetic and were used 
for the study.  
 
Animal and treatment 
The diabetic rats induced- STZ were divided randomly into 3 
groups consisting of 5 rats per group. Group 1 has contained 
of diabetic rats given 1 ml phosphate buffer (diabetic control 
group). Group 2 are the diabetic rats treated with 150 mg/kg 
metformin (CCM Pharmaceutical, Malaysia) and group 3 are 
the diabetic rats which received 50 mg/kg V. amygdalina 
aqueous extract. Metformin and V. amygdalina aqueous 
extracts were freshly prepared according to the BW of the rats 
and were dissolved in 1 ml of phosphate buffer saline 
(Nacalai Tesque, Japan) and 1 ml of distilled water, 
respectively. Treatments were given twice daily, at 9 a.m. and 
4 p.m. for 28 days. One group of non-diabetic rats (n=5) or 
clean rats was used as normal control (NC). Body weight was 
recorded weekly.  
 
Blood collection and biochemical analysis 
After 28 days, all the rats were fasted overnight before 
euthanization by intra peritonal injection of sodium 
pentobarbital (Alfasan Woerden, Holland). Approximately 5 
ml of blood was collected through cardiac puncture and 
transferred into a blood plain vacuum tube. The blood 
samples were centrifuged at 4500 rpm for 10 min for serum 
separation. The serum obtained was evaluated for lipid profile 
test and FBG level.  
 
Insulin secretion assay  
The insulin secretion assay was done by using Insulin ELISA 
kit (ab10057, Abcam). This kit employs an antibody specific 
for insulin coated on a 96-well plate. Serum samples were 
pipetted into the well plate and procedures were followed as 
to manual. The intensity of colour formation is proportional to 
the amount of insulin bound, which was measured at 450 nm 
by microplate reader (Model 680, Biorad). 
 
Statistical analysis 
Data were expressed as Mean ± SEM. The statistical analysis 
were analyzed using Kruskal Wallis test to evaluate the 
differences in the lipid profile test, FBG, mean insulin 
absorbance between each group. Results with (aP value < 
0.05) were considered statistically significant. 
 
3. Results and Discussion 
Body weight (BW) and relative organ weight (ROW)  
V. amygdalina traditionally claim has a potential in lowering 
blood glucose among diabetes patients. In order to confirm 
the effectiveness of V. amygdalina and to prove the claim by 
traditional practice, aqueous extract of local Malaysian V. 
amygdalina leaves were used in this study in order to mimic 
as close as possible. Most of the traditional healers used water 
to make herbal decoctions juices. In addition, the aqueous 
extract was chosen as water is the universal solvent, non-toxic 
and does not interfere with the end product of extraction.  
The group contains of clean rats or normal control (NC) 
showed a slightly gain in body weight throughout the 
experiment. However, diabetic induced groups have shown a 
pattern of decrease in BW throughout the 28 days of 
experimental period. Diabetic induced rats treated with V. 
amygdalina aqueous extract showed increased of weight in 
Day 15. Despite that, there were no significant differences in 
BW and ROW between each group (Table 1 and Table 2). 
There were no organs abnormalities observed in all the rats. 
 
Table 1: The body weight recorded for each group in one week of 





NC DC Metformin VA 
Week 0 403.3 ± 9.1 385.8±12.1 388.4 ± 8.5 386.4 ± 23.2 
Week 1 403.0 ± 11.4 357.0±10.3 364.4 ± 10.3 366.2 ± 28.7 
Week 2 414.8 ± 11.1 360.0±10.0 364.0 ± 11.9 371.0 ± 32.2 
Week 3 419.0 ± 9.1 358.3 ± 9.1 363.8 ± 12.9 369.2 ± 33.4 
Week 4 408.3 ± 11.1 327.5±11.8 339.8 ± 17.5 343.0 ± 37.9 
Value were expressed as mean ± SEM, n=5, *P<0.05, Kruskal 
Wallis test not significant. NC = normal control, DC = diabetic 
control, Metformin = 150 mg/kg/BW metformin-treated diabetic, 
VA = 50 mg/kg/BW V.amgdalina aqueous extract-treated diabetic. 
 
Table 2: The relative organ weight (ROW) recorded for each group 





NC DC Metformin VA 
Liver 2.7 ±0.1 3.3±0.2 3.4 ± 0.2 3.4±0.2 
Heart 0.4±0.02 0.4±0.03 0.4 ± 0.02 0.4±0.02 
Kidney 0.6±0.04 0.8 ± 0.1 0.8 ± 0.04 0.8 ± 0.1 
Value were expressed as mean ± SEM, n=5, *P<0.05, Kruskal 
Wallis test not significant. NC = normal control, DC = diabetic 
control, Metformin = 150 mg/kg/BW metformin-treated diabetic, 
VA = 50 mg/kg/BW V. amgdalina aqueous extract-treated diabetic. 
 
Lipid profile test 
In this present study, V. amygdalina aqueous extract 
possessed antidiabetic characteristic which the ability to 
reduce blood glucose level. There were no significant 
differences in the level of total cholesterol and LDL 
cholesterol between each group. V. amygdalina aqueous 
extract-treated group has significant increase in total 
cholesterol/HDL ratio compared to others group. NC group 
has significant lower level in triglycerides, HDL cholesterol 
and FBG level among each group. V. amygdalina aqueous 
extract-treated group has significant reduced in triglycerides, 
HDL cholesterol and FBG level compared to metformin 
treated rats and diabetic control group (Table 3). Metformin 
treated rats have shown a slight increase in FBG as compared 
to diabetic control rats.  
 
Table 3: Lipid profile test and fasting blood glucose level after 28 days of treatment 
 
GROUP NC DC Metformin VA 
Total cholesterol (mmol/L)a 1.50±0.04 1.80±0.11 1.88 ± 0.15 1.68 ± 0.07 
Triglycerides (mmol/L)a 0.42±0.06* 0.96±0.29 0.90 ± 0.17 0.45±0.03** 
HDL cholesterol (mmol/L)a 0.31±0.01* 0.49±0.05 0.36 ± 0.03 0.32±0.02** 
LDL cholesterol (mmol/L)a 1.00 ± 0.02 0.87±0.11 1.11 ± 0.10 1.15 ± 0.08 
Total cholesterol/HDL ratio 4.88 ± 0.15 3.73 ± 0.16 5.30 ± 0.33 5.32 ± 0.42* 
Fasting blood glucose (mmol/L)a 6.78±0.68* 10.90±1.49 14.70±2.38 8.80±1.06** 
aValues were expressed as mean ± SEM. (n=5). P value < 0.05. * Significantly different from other groups, 
** significantly different among diabetic induced groups. NC = normal control, DC = diabetic control, 
Metformin = metformin-treated diabetic, VA = V. amgdalina aqueous extract-treated diabetic. 
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Diabetic rats treated with V. amygdalina aqueous extract 
showed a significant reduced in triglycerides, HDL 
cholesterol and FBG level. These findings were correlates to 
the previous findings that describe V. amygdalina ethanol 
extract significantly reduced glucose level and decreased 
triglycerides level, and V. amygdalina aqueous extract 
significantly decreased triglycerides level and normalized 
cholesterol concentrations (Ekpo et al., 2007; Atangwho et 
al., 2010; Trease and Evans, 1989) [10, 4, 44]. A related study 
from Ghana also showed that the leaf of Vernonia amygdalina 
either young leaf or old leaf has possess antidiabetic property. 
Both young leaf and old leaf significantly reduce the levels of 
blood glucose (Asante et al., 2016) [5]. The decreasing of body 
weight in diabetic control group was observed throughout the 
experiment period but not significantly different (p>0.05). 
Severel studies have shown the relationship between 
hyperglycemia and decreased body weight of diabetic 
animals. STZ by producing diabetes or hyperglycemia and 
hypoinsulinemia causes reduction in the body weight of 
diabetic animals (Nwanjo, 2005) [32]. The obligatory renal 
water loss along with hyperosmolarity in diabetes triggered 
the osmoreceptor of the thirst centre of the brain and 
polydipsia which resulted in water intake. Hence, this 
catabolic effect resulted in weight loss (Akah et al., 2009) [1]. 
The treatment with V. amygdalina aqueous extract showed the 
increased of body weight. The rats gained the body weight 
within 15 days. However, the data was not statistically 
significant. Previous finding was reported that the body 
weight of diabetic induced rats treated with V. amygdalina 
extract slightly increase after a few days of treatment (Zafar 
and Hassan, 2010) [50]. ROW did not show any significant 
differences between each group and there were no organs 
abnormalities, gross lesions or enlargement of organs 
observed in all the rats. The observations were similar to one 
of the previous studies, which were reported that there were 
no significant differences in wet organ weight and no 
significant abnormalities in the vital organs in diabetic treated 
V. amygdalina extract (Akah et al., 2009) [1].  
 
Insulin secretion assay 
The insulin secretion assay showed that there were no 
significant changes in the level of insulin in the diabetic rats 
treated with V. amygdalina extract as compared to metformin 
treated group. Metformin- treated group has the highest 
insulin level (Table 4). 
 
Table 4: The mean absorbance for insulin level after 28 days of 
experiment 
 
GROUP NC DC Metformin VA 
Mean absorbance 
(nm)a 
0.17±0.003* 0.14±0.002 0.17±0.009** 0.14±0.008 
aValues were expressed as mean ± SEM. (n=5). P value < 0.05. * 
Significantly different from other groups, **significantly different 
among diabetic induced groups. NC = normal control, DC = diabetic 
control, Metformin = metformin-treated diabetic, VA = V. 
amgdalina aqueous extract-treated diabetic. 
 
The result is in line with the previous study which reported 
that metformin decreased the plasma glucose level by 
enhanced the insulin release (Yoshida et al., 2009) [49]. Based 
on the result, it was showed that Malaysian V. amygdalina act 
as glucose lowering agent without regulate the insulin action. 
There was a slight increase in fasting blood glucose of 
metformin-treated group as compared with diabetic control. 
Metformin is currently the drug of first choice for the 
treatment of T2DM and being prescribed to at least 120 
million people worldwide. Despite that, the exact molecular 
mechanism of action of metformin has not been fully 
elucidated. Metformin is regarded as an anti-hyperglycemic 
agent because it lowers blood glucose concentrations in 
T2DM, reduces insulin resistance and significantly lowering 
plasma fasting glucose level. Metformin could be activated 
insulin receptor expression and tyrosine kinase activity, thus 
improve insulin sensitivity (Gunton et al., 2003) [16]. In 
addition, the action of metformin to inhibit complex I of the 
respiratory chain, mitochondrial respiration and ATP 
synthesis, has been proposed (Rutter et al., 2003) [37]. 
Although metformin is generally considered to have no direct 
effect on the pancreatic islet β-cell, an early report 
demonstrated a dose-related inhibition of glucose-stimulated 
insulin secretion and insulin biosynthesis by metformin 
(Schatz et al., 1972) [40]. An observation usually attributed to 
the increase in peripheral insulin sensitivity (Rutter et al., 
2003) [37]. Clinical studies also show that metformin may 
reduce plasma dipeptidyl peptidase-4 activity and increase 
circulating levels of glucagon-like peptide 1 (GLP-1) (Maida 
et al., 2011) [28]. Another research study shows that metformin 
activates AMPK activity in MIN6 cells and human islets of 
Langerhans and inhibits insulin release (Isabelle et al., 2004) 
[21], therefore, might reduce the sensitivity of insulin and 
increases glucose level. This kind of action might have 
occurred in our present study, thus the FBG levels of 
metformin-treated diabetic rats slightly increase as compared 
to diabetic control group. The effects of metformin on T2DM 
been somewhat contradictory, with some reports 
demonstrating that metformin improve insulin secretion, 
increase insulin gene expression and insulin content, and 
reduce islet apoptosis in human islets exposed to high glucose 
(Marchetti et al., 2004) [29]. In contrast, metformin was also 
reported to inhibit insulin secretion (Isabelle et al., 2004) [21], 
impairs glucose-responsivity and enhances susceptibility to 
apoptosis (Kefas et al., 2004) [22]. Therefore, these 
discrepancies possibly reflect variation in experimental 
models, species-specific differences, doses of metformin and 
duration of metformin exposure, which need further study. 
The antidiabetic property of the V. amygdalina might have an 
association with its phytochemical contents. Our previous 
study on phytochemicals analysis by standard method 
revealed that the aqueous extract of Malaysian V. amygdalina 
leaves were contained of flavonoids, tannin, saponin and 
terpenoids. ATR-FTIR spectrum also demonstrated the 
present of phenol and a high content of flavonoids and 
terpenoids (Yusmazura et al., 2016) [48]. Previous research on 
other localities of V. amygdalina have found polyphenols, 
glycosides, steroids, carbohydrates, alkaloids, saponin, tannin, 
flavonoids and glycosides in the aqueous extract of V. 
amygdalina leaves (Akah et al., 2009; Siddiqui et al., 2009) [1, 
42]. Thus, the main difference between Malaysian V. 
amygdalina and any other reported V. amygdalina is in the 
content of terpenoids. Terpenoids is one of the plant 
antioxidants substances besides ascorbic acid and tocopherols 
which perform an important function in human and plant. 
During the assessing of plant antioxidant activity, an 
important point to consider is the interaction with other 
antioxidants. Flavonoids also act as an antioxidant (Arhoghro 
et al., 2009) [2]. The combinations of hydrophilic and 
lipophilic antioxidants may exert synergistic effects which 
could significantly increase the potential of the antidiabetic 
property. One of the major triggers in inducing hyperglycemia 
in diabetic complications has been proposed was an increase 
of oxidative stress. Hyperglycemia is the main symptom of 
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diabetes, which generates reactive oxygen species (ROS) and 
eventually causes lipid peroxidation and membrane damage 
(Pate et al., 2010) [34]. Lipid peroxidation also plays a role in 
the long term complications of diabetes (Logani and Davis, 
1979) [26]. Thus, antioxidants play an important role to protect 
the human body against damage by reactive oxygen species 
(Lollinger, 1981) [27]. 
Therefore, the effectiveness of Malaysian local V. amygdalina 
may be due to the high content of flavonoids. Previous studies 
reported that flavonoids act as an insulin secretagogues or 
insulin mimetics (Collier et al., 1990) [7]. This flavonoids 
probably influencing the pleiotropic mechanisms to attenuate 
diabetic complications with protecting β-cells against ROS-
mediated damage, leading to cellular antioxidant defenses and 
minimizing hyperglycemia in STZ-induced diabetes (Collier 
et al., 1990) [7]. Thus, the Malaysian V. amygdalina extract 
might have insulin like activity. The anti-hyperglycemic 
effect of the extract may be due to an increase in peripheral 
glucose consumption as well as protection against oxidative 
damage in diabetic rats (Halliwell and Gutteridge, 1985; 
Logani and Davis, 1979; Saghizadeh et al., 1996) [17, 26, 39]. 
There is also a possibility that the Malaysian V. amygdalina 
extract reduces the effect of inflammatory cytokine release 
during diabetes which may be one of the causative agents for 
the tissue distraction and insulin resistance (Saghizadeh et al., 
1996) [39]. However the exact mechanism of V. amygdalina 




Malaysian V. amygdalina possessed antidiabetic activity. 
Based on the findings, together with our previous study, the 
effect of Malaysian V. amygdalina leaves as an antidiabetic 
agent may be due to the high content of flavonoids and 
terpenoids. As compared to other locality of V. amygdalina, 
the present of terpenoids and flavonoids in Malaysian V. 
amygdalina leaves become a good combination in order to act 
as an antidiabetic agent. The synergistic effects of both 
compounds make the plant more effective not only in 
lowering blood glucose but also as prevention against ROS in 
the body. Flavonoids mimic the insulin in order to reduce 
blood glucose while terpenoids act as an antioxidant and 
protect from organ damage. As a final conclusion, the 
findings in this present study clearly indicate an exciting 
promising of alternative potent antidiabetic drug from 
Malaysian V. amygdalina. 
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